Clinical Oncology - 2017;4(04)

Clinical Oncology

DECEMBER 05, 2017

Clinical Oncology

DECEMBER 05, 2017

[Complex therapy of bladder cancer]

LANDHERR László

[Bladder cancer is the most common malignancy involving the urinary system. Urothelial (formerly called transitional cell) carcinoma is the predominant histologic type in the developed countries, where it accounts for approximately 90 percent of all bladder cancers. The optimal management of nonmuscle invasive urothelial cancer is highly important. For patients with muscle invasive cancer the gold standard treatment is the cystectomy. If the patient unable or unwilling to undergo radical... tovább »

Clinical Oncology

DECEMBER 05, 2017

[Hematopoetic stem cell transplantation for pediatric non-hematological solid tumors]

HAUSER Péter, KRIVÁN Gergely

[High-dose chemotherapy followed by stem cell rescue or allogeneic stem cell transplantation in the treatment of solid tumor with non-hematologic origin applied for more than three decades. High-dose chemotherapy with stem cell rescue is the part of standard fi rst line therapy for several chemosensitive tumors with unfavorable outcome (neuroblastoma, Ewing-sarcoma, medulloblastoma), and also successfully applied in certain therapy-resistant or recurrent solid tumors (germ cell tumors,... tovább »

Clinical Oncology

DECEMBER 05, 2017

[Current treatment therapy of prostate cancer]

KULLMANN Tamás, KOCSIS Károly, SZEPESVÁRY Zsolt

[Prostate cancer is a frequent and usually slowly progressing malignancy. Promising opportunities and risks to avoid may occur along its diagnosis and treatment. The chance of early detection is high. The localised disease can be cured by radical prostatectomy and radiotherapy with equal probability. The post-prostatectomy biochemical failure may be controlled by radiotherapy. Even oligometastatic tumours can be cured by harmonised local treatment modalities. The survival of metastatic disease... tovább »

Clinical Oncology

DECEMBER 05, 2017

[Inhibition of proteasome in cancer therapy]

KOPPER László

[The ubiquitin-proteasome pathway is the most important element in the regulation of intracellular protein metabolism. Its main function is the degradation of the unnecessary proteins either as part of normal metabolic balance or in case of misfolding or part of the deregulation as in cancer cells using proteolytic enzymes. The importance of this pathway has been acknowledge by Nobel prize. In certain diseases as in several malignancies, where the ubiquitin-proteasome pathway is not able to... tovább »

Clinical Oncology

DECEMBER 05, 2017

[Burnout syndrome - prevention and treatment]

SZY Ágnes

[The defi nition of burnout syndrome was established due to the recognition of changes that practising physicians experienced in their affective state and behaviour as well as the observation of physical symptoms that put their health at risk. Burnout syndrome can be characterised by a triadic set of factors: emotional exhaustion, depersonalisation, and decline of professional achievement. The present article aims to describe burnout syndrome with regard to the fact that similarities and... tovább »

Clinical Oncology

DECEMBER 05, 2017

[Protontherapy]

LAKOSI Ferenc, HADJIEV Janaki, CSELIK Zsolt, GULYBÁN Ákos

[Radiotherapy with protons is a promising technology in the fi eld of modern radiation oncology. From a physical point of view, radiotherapy with protons has important advantages compared to the currently used photons due to its unique energy absorption profi le, which may result in a better local tumor control and reduced radiation-induced side effects. Increasing number of patients is treated with protons and carbon-ions. Our report aim to present the current status of proton radiotherapy... tovább »